They came in with fourteen names and left with one.
The brief was a grain-based snack targeting urban millennial parents. The founder had been workshopping names for six months. She had a spreadsheet with 47 entries, color-coded by "vibe." None of them were available as a .com. Three were already trademarked. Two were registered in competing categories.
We started where we always start: with the phonetics of the category. Snack names cluster around hard consonants — the K, the CR, the CH. They signal crunch. They signal speed. They signal the satisfying physics of the product. We needed something that lived in the same sonic neighborhood but owned a distinct corner.
The dead ends were instructive. GRAINFIELD tested as "old and tired." SNAKTIV sounded like an energy supplement. BITELAB felt clinical. The finalist debate lasted three days. The question wasn't which name was best — it was which name had room to grow into a $50M brand without needing to be explained.
The winner: GRAVEL — short, textural, unexpected, and completely available. Trademark cleared in 72 hours across three classes. The brand launched six months later. It's now in Whole Foods in 14 states.
The investors said "it sounds like a bank." That was the point.
The founder had a problem that's more common than you'd think: his fintech product was genuinely sophisticated, but every name his team generated sounded like a startup. Zapp. Flowly. Fundra. The investors he was courting — family offices and institutional LPs — parsed names as signals of seriousness. He needed something that could sit in a boardroom.
The linguistic brief was precise: Latin or Old French root (trust by association), two syllables maximum (authority), ending in a hard consonant or a vowel that stops cleanly (no trailing softness), and zero overlap with the existing fintech namespace — which, by 2024, was comprehensively colonized.
We ran three naming sprints over two weeks. The finalist debate came down to VERITY and ARDENT. ARDENT tested better with founders. VERITY tested better with the people who write the checks. The choice was obvious.
VERITY closed its Series A at $18M four months after launch. The lead investor cited brand clarity as a differentiator in their thesis memo.
The Naming Playbook
The 48-page framework we use on every engagement — from linguistic brief to trademark clearance. Used by 340+ founders to avoid the most expensive naming mistakes.
Audit your current name. In 30 seconds.
Enter any brand name and get an instant read on phonetics, memorability, domain availability, and trademark risk. No signup required.
Enter a name above to begin
Six constraints. Fourteen markets. One word.
The brief arrived six weeks before a global regulatory filing deadline. A mid-stage biotech had a breakthrough oncology compound ready for Phase III trials — and a working name that had just been flagged by their IP counsel as too close to an existing brand in the EU. They needed a new name that could survive the FDA, EMA, and PMDA simultaneously.
Pharmaceutical naming operates under a different physics than consumer naming. The FDA's PDUFA guidelines, the EMA's CHMP naming criteria, and the WHO's INN conventions all impose constraints that most naming frameworks weren't built to handle. We had worked in this space before. We knew the rules.
The constraint matrix was the tightest we'd ever operated under. Six hard requirements, zero flexibility on any of them. We ran 400 candidate names through automated screening, whittled to 40 for linguistic review, to 12 for regulatory pre-screening, to 3 for stakeholder testing. The finalist debate lasted four hours.
The winning name: ARVEX. Two syllables. No negative semantic associations across all 14 markets. Cleared pre-screening with the FDA and EMA simultaneously — a first in our studio's history. The compound enters Phase III under this name.
